How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

While previous assessments categorized AI-assisted cyberattacks as experimental, current data suggests generative AI is now a mature, industrialized component of offensive operations.

Google caught the first zero-day exploit built with AI assistance. Criminal and state backed hackers are using AI models to ...

Google identified the first malicious AI use for a zero-day 2FA bypass in an open-source admin tool, accelerating threat ...

Criminal hackers have used artificial intelligence to develop a working zero-day exploit, the first confirmed case of its ...

If you are a community college student building Python skills alongside microcontrollers and robotics projects, the PCEP-30-02 certification is your fastest, most credible way to validate those skills ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Andrew covers the biopharma industry, scientific research, and public health across the continent. You can reach Andrew confidentially on Signal at drewqjoseph.71. LONDON — In the year-plus since ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...